Having a high-deductible health plan was associated with a nearly 5-month delay in the diagnosis of metastatic cancer.
Patients who received denosumab had a significant improvement in disease-free survival and bone metastasis-free survival.
The incidence of advanced lung cancer declined by 3 cases per 100,000 people per year in 2015-2018 relative to 2004-2014.
The overall response rate was 66.7%, and the median duration of response was 17.5 months.
Among patients with ER+/HER2+ breast cancer, the median survival after distant recurrence increased from 2.3 years in 2000 to 4.8 years in 2019.
Acupuncture was associated with improvements in symptoms and quality of life.
There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
Rivoceranib produced responses whether or not patients had received prior treatment with a VEGFR TKI.
The estimated 2-year RFS rate for patients with MPR was 93.3% (95% CI, 87.2%-99.9%) after a median follow-up of 27.9 months.
The study population included patients aged 18 years and older who had histologically confirmed desmoplastic melanoma that was resectable.
The 3-drug strategy combines targeted therapy against BRAF (vemurafenib) and MEK (cobimetinib), and immunotherapy (atezolizumab).
Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.
In all, 32 patients had a response, translating to an ORR of 66.7%.
Among the TEAEs of clinical interest, the most frequent were infections, bleeding, cardiac events, anemia, and neutropenia and neutrophil count decrease.
Parsaclisib is a potent, highly selective, next-generation phosphoinositide 3-kinase-delta (PI3K-delta) inhibitor.
Based on preliminary data from this study, sugemalimab was granted breakthrough therapy designation for adult patients with R/R ENKTL in 2021.
At a median follow-up of 12.6 months, the overall response rate was 51.6% and the CR rate was 39.4%.
Results of a phase 3 trial suggest that brentuximab vedotin (Bv) with doxorubicin (A), vincristine (V), etoposide (E), prednisone (P), and cyclophosphamide (C) should be the new standard frontline therapy among youth with high-risk classic Hodgkin lymphoma (cHL).
The patients were randomly assigned 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily.
The percentage of patients with stage I disease increased from 23.5% in 2010 to 29.1% in 2017.